Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Outlook on the Targeted Protein Degradation Market to 2030 - Includes Recent Developments and Upcoming Trends

      Research and Markets Logo

      News provided by

      Research and Markets

      Feb 21, 2020, 10:00 ET

      Share this article

      Share this article


      DUBLIN, Feb. 21, 2020 /PRNewswire/ -- The "Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

      This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

      One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030.

      The report features likely distribution of the current and forecasted opportunity across

      • Type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors)
      • Therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas),
      • Route of administration (oral, intravenous and others),
      • Key contributing technologies and
      • Key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

      Key Topics Covered:

      1. PREFACE

      2. EXECUTIVE SUMMARY

      3. INTRODUCTION
      3.1. Context and Background
      3.2. Protein Homeostasis
      3.3. Post Translational Protein Modifications
      3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS)
      3.4.1. Structure and Functions of Ubiquitin
      3.4.2. Overview of the UPS
      3.4.2.1. Components of the UPS
      3.4.2.2. Ubiquitin-based Protein Degradation Pathway
      3.5. Therapeutic Applications of the UPS
      3.6. Ubiquitin Enzyme Inhibitors
      3.6.1. Advantages and Challenges
      3.7. Overview of Targeted Protein Degradation
      3.7.1. Historical Development of Protein Degraders
      3.7.2. Types of Protein Degraders
      3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
      3.7.2.2. Other Chimeric Protein Targeting Molecules
      3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
      3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
      3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
      3.7.2.3. Epichaperome Inhibitors
      3.7.2.4. Hydrophobic Tags
      3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
      3.7.2.6. Molecular Glues
      3.7.2.7. Protein Homeostatic Modulators
      3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
      3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
      3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors
      3.8. Growth Drivers and Roadblocks
      3.9. Recent Developments and Upcoming Trends

      4. CURRENT MARKET LANDSCAPE
      4.1. Chapter Overview
      4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
      4.2.1. Analysis by Type of Protein Degrader
      4.2.2. Analysis by Phase of Development
      4.2.3. Analysis by Therapeutic Area
      4.2.4. Analysis by Target Indication
      4.2.5. Analysis by Type of Target Protein
      4.2.6. Analysis by Type of Target Enzyme
      4.2.7. Analysis by Type of Therapy
      4.2.8. Analysis by Route of Administration
      4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
      4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
      4.4.1. Analysis by Year of Establishment
      4.4.2. Analysis by Size of Company
      4.4.3. Analysis by Type of Protein Degrader
      4.4.4. Analysis by Location of Headquarters
      4.4.5. Leading Developers: Analysis by Number of Drug Candidates

      5. COMPANY PROFILES
      5.1. Chapter Overview
      5.2. Developers with Late-stage Clinical Candidates
      5.2.1. Radius Health
      5.2.1.1. Company Overview
      5.2.1.2. Financial Information
      5.2.1.3. Targeted Protein Degradation-based Drug Portfolio
      5.2.1.3.1. Elacestrant (RAD1901)
      5.2.1.4. Recent Developments and Future Outlook
      5.2.2. Celgene
      5.2.2.1. Company Overview
      5.2.2.2. Financial Information
      5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
      5.2.2.3.1. Avadomide (CC-122)
      5.2.2.3.2. Iberdomide (CC-220)
      5.2.2.4. Recent Developments and Future Outlook
      5.2.3. Sanofi Genzyme
      5.2.3.1. Company Overview
      5.2.3.2. Financial Information
      5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
      5.2.3.3.1. SAR439859
      5.2.3.4. Recent Developments and Future Outlook
      5.3. Developers with Preclinical / Early-stage Clinical Candidates
      5.3.1. Arvinas
      5.3.2. Captor Therapeutics
      5.3.3. Genentech
      5.3.4. Kymera Therapeutics
      5.3.5. Mission Therapeutics
      5.3.6. Progenra
      5.3.7. Zenopharm

      6. CLINICAL TRIAL ANALYSIS
      6.1. Chapter Overview
      6.2. Scope and Methodology
      6.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
      6.3.1. Analysis by Trial Registration Year
      6.3.2. Geographical Analysis by Number of Clinical Trials
      6.3.3. Geographical Analysis by Enrolled Patient Population
      6.3.4. Analysis by Type of Protein Degrader
      6.3.5. Analysis by Phase of Development
      6.3.6. Analysis by Study Design
      6.3.7. Analysis by Type of Sponsor / Collaborator
      6.3.8. Most Active Players: Analysis by Number of Registered Trials
      6.3.9. Analysis by Trial Focus
      6.3.10. Analysis by Therapeutic Area
      6.3.11. Analysis by Clinical Endpoints

      7. KOL ANALYSIS
      7.1. Chapter Overview
      7.2. Scope and Methodology
      7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials
      7.3.1. Analysis by Designation
      7.3.2. Analysis by Phase of Development and Type of Protein Degrader
      7.3.3. Analysis by Focus Therapeutic Area
      7.3.4. Analysis by Type of Organization
      7.3.5. Analysis by Location of Organization
      7.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
      7.4. Prominent Key Opinion Leaders (KOLs)
      7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
      7.6. Profiles of Most Active KOLs
      7.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
      7.6.2. Profile: KOL B (Celgene)
      7.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
      7.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
      7.6.5. Profile: KOL E (Samus Therapeutics)
      7.6.6. Profile: KOL F (Stanford Women Cancer Center)
      7.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
      7.6.8. Profile: KOL H (University of Toledo)

      8. PARTNERSHIPS AND COLLABORATIONS
      8.1. Chapter Overview
      8.2. Partnership Models
      8.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships
      8.3.1. Analysis by Year of Partnership
      8.3.2. Analysis by Type of Partnership
      8.3.3. Analysis by Type of Protein Degrader
      8.3.4. Analysis by Technology Platform
      8.3.5. Analysis by Therapeutic Area
      8.3.6. Most Active Players: Analysis by Number of Partnerships
      8.3.7. Geographical Analysis
      8.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
      8.3.7.2. Intercontinental and Intracontinental Agreements

      9. FUNDING AND INVESTMENT ANALYSIS
      9.1. Chapter Overview
      9.2. Types of Funding
      9.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
      9.3.1. Analysis by Number of Funding Instances
      9.3.2. Analysis by Amount Invested
      9.3.3. Analysis by Type of Funding
      9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Types of Degraders
      9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
      9.3.6. Analysis by Amount Invested across Different Technology Platforms
      9.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
      9.3.8. Most Active Investors: Analysis by Participation
      9.3.9. Geographical Analysis by Amount Invested
      9.4. Concluding Remarks

      10. MARKET SIZING AND OPPORTUNITY ANALYSIS
      10.1. Chapter Overview
      10.2. Key Assumptions and Forecast Methodology
      10.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
      10.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030
      10.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
      10.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030
      10.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030
      10.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030
      10.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030
      10.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030
      10.4.1.6. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
      10.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
      10.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030
      10.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030
      10.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030
      10.4.2.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030
      10.4.2.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030
      10.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
      10.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030
      10.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030
      10.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030
      10.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
      10.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030
      10.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030
      10.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030
      10.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2020-2030

      11. EXECUTIVE INSIGHTS

      12. CONCLUDING REMARKS
      12.1. Chapter Overview
      12.2. Key Takeaways

      13. APPENDIX 1: TABULATED DATA

      14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

      Companies Mentioned

      • 5AM Ventures
      • 6 Dimensions Capital
      • AbbVie
      • Abingworth
      • Abramson Cancer Center, University of Pennsylvania
      • Advantech Capital
      • Aisling Capital
      • AJU IB Investment
      • Alexandria Venture Investments
      • Alfred Berg
      • Almac Discovery
      • Altitude Life Science Ventures
      • AM Capital
      • Amgen
      • Amsterdam UMC
      • Amzak Health
      • AnnJi Pharmaceutical
      • ARCH Venture Partners
      • ARENSIA Exploratory Medicine
      • Arpeggio Biosciences
      • Artios Pharma
      • Arvinas
      • Astex Pharmaceuticals
      • AstraZeneca
      • Atlas Venture
      • Aurigene Discovery Technologies
      • Avista Pharma Solutions
      • Barbara Ann Karmanos Cancer Center
      • Bayer
      • Beactica
      • BeiGene
      • Beijing Huarong Sangel Venture Capital
      • Bellco Capital
      • Bessemer Venture Partners
      • Beverly Hills Cancer Center
      • BeyondSpring Pharmaceuticals
      • Biogen
      • BioRap Technologies
      • BioStrategics Consulting
      • BioTheryX
      • Boehringer Ingelheim
      • Borun Investment
      • Boston Biochem
      • Boxer Capital, Tavistock Group

      For more information about this report visit https://www.researchandmarkets.com/r/pyg4x1

      Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.